Table 2.

Anti-BCMA bispecific antibodies after BCMA targeting therapies

Investigational agent (study)	ADC exposed pts % (no.)	CAR-T exposed pts % (no.)	ORR (no.)	CRR or better (no.)	ORR in general population
Teclistamab (MajesTEC1) [42]	64 (16)	44 (11)	40 (10)	20 (5)	62
Elranatamab (MagnetisMM-1) [43–44]	14.4 (8)	16.4 (9)	54 (7)	23 (3)	64

ADC Antibody–drug conjugate; BCMA B cell maturation antigen; CAR-T chimeric antigen receptor T cell therapy; CRR complete response rate; no. number; ORR overall response rate; pts patients